Saturday - February 07, 2026

Category Archives: Marketing & Sales

Myelofibrosis Clinical Trials Outlook: Competitive Intelligence, Regulatory Progress, Emerging Therapies, Mechanisms of Action, and Administration Pathways – DelveInsight

Myelofibrosis Clinical Trials Myelofibrosis Companies include Incyte, Keros Therapeutics, Karyopharm Therapeutics, Celgene, PharmaEssentia, Novartis, SecuraBio, Pharmaxis, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Kartos Therapeutics, Menarini Group, Telios Pharma, MorphoSys, Roche, and others. DelveInsight’s latest report, … Continue reading →

Bispecific Antibody Competitive Landscape Analysis: Strategic Intelligence Covering 180+ Companies and 250+ Therapeutic Candidates by DelveInsight

Bispecific Antibody Competitive Landscape Bispecific Antibody Companies include I-MAB Biopharma, Bristol Myers Squibb, AstraZeneca, BioNTech, Genmab, Compass Therapeutics, Innovent, Regeneron Pharmaceuticals, Aurigene Oncology, Curis, Akeso, Summit Therapeutics, Roche, Merus, Adimab, Creative Biolabs, Amgen, Zymeworks, Xencor, Novo Nordisk, MacroGenics, among others, … Continue reading →

Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape Report: Featuring 200+ Companies and 220+ Therapeutic Candidates, analyses DelveInsight

Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape An extensive review of one of the most rapidly advancing targeted cancer therapy classes, covering pipelines, clinical advancements, partnerships, and long-term outlook DelveInsight, a prominent life sciences market research and business consulting organization, … Continue reading →

Wilson Disease Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Deep Genomics Inc, DepYmed Inc, Enveda Biosciences Inc, Generation Bio Co, Vivet Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Wilson Disease pipeline constitutes 5+ key companies continuously working towards developing 5+ Wilson Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Synovial Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Advenchen Lab, Ipsen, Daiichi Sankyo, EpiZyme, Merck, Immunocore, Novartis

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Synovial Sarcoma pipeline constitutes 15+ key companies continuously working towards developing 20+ Synovial Sarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Multiple Sclerosis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →